Skip to main content

Research Repository

Advanced Search

All Outputs (12)

SPHINX-based combination therapy as a potential novel treatment strategy for acute myeloid leukaemia (2023)
Journal Article
Wodi, C., Belali, T., Morse, R., Porazinski, S., & Ladomery, M. (2023). SPHINX-based combination therapy as a potential novel treatment strategy for acute myeloid leukaemia. British Journal of Biomedical Science, 80, 11041. https://doi.org/10.3389/bjbs.2023.11041

Introduction: Dysregulated alternative splicing is a prominent feature of cancer. The inhibition and knockdown of the SR splice factor kinase SRPK1 reduces tumour growth in vivo. As a result several SPRK1 inhibitors are in development including SPHIN... Read More about SPHINX-based combination therapy as a potential novel treatment strategy for acute myeloid leukaemia.

Understanding Hydrogen: Lessons to be learned from physical interactions between the inert gases and the globin superfamily (2022)
Journal Article
Hancock, J. T., Russell, G., Craig, T. J., May, J., Morse, H. R., & Stamler, J. S. (2022). Understanding Hydrogen: Lessons to be learned from physical interactions between the inert gases and the globin superfamily. Oxygen, 2(4), 578-590. https://doi.org/10.3390/oxygen2040038

Hydrogen gas (molecular hydrogen, H2) has significant effects in a range of organisms, from plants to humans. Many inert gases have been reported to have similar effects, and such responses may be most pronounced when cells are stressed. Xenon (Xe),... Read More about Understanding Hydrogen: Lessons to be learned from physical interactions between the inert gases and the globin superfamily.

A novel in vitro 3D model of the human bone marrow to bridge the gap between in vitro and in vivo genotoxicity testing (2022)
Journal Article
Vernon, A. R., Pemberton, R. M., & Morse, H. (2022). A novel in vitro 3D model of the human bone marrow to bridge the gap between in vitro and in vivo genotoxicity testing. Mutagenesis, 37(2), 112-129. https://doi.org/10.1093/mutage/geac009

The regulatory 2D in vitro micronucleus (MN) assay is part of a battery of tests, used to test for genotoxicity of new and existing compounds before they are assessed in vivo (ICH S2). The 2D MN assay consists of a monolayer of cells, whereas the in... Read More about A novel in vitro 3D model of the human bone marrow to bridge the gap between in vitro and in vivo genotoxicity testing.

The stromal cell line HS-5 is an alternative mesenchymal stem cell source for the development of a 3D bone marrow model (2015)
Journal Article

Developing a novel three-dimensional (3D) in vitro model of the bone marrow microenvironment using bone mar- row mesenchymal stem cells (BM-MSCs) in commercial matrices involves a series of distinct processes. This starts with selecting an appropriat... Read More about The stromal cell line HS-5 is an alternative mesenchymal stem cell source for the development of a 3D bone marrow model.

Determination of the appropriate gene for real-time PCR analysis of the immotalized stromal cell line HS-5 in 2D and 3D culture following melphalan exposure (2015)
Journal Article

Although gene expression analysis using real-time quan- titative reverse transcription-polymerase chain reaction (RT-qPCR) is an accurate method to evaluate cell activi- ties and phenotypes, the reliability of the analysis depends on the selection of... Read More about Determination of the appropriate gene for real-time PCR analysis of the immotalized stromal cell line HS-5 in 2D and 3D culture following melphalan exposure.

Development of a novel, physiologically relevant cytotoxicity model: Application to the study of chemotherapeutic damage to mesenchymal stromal cells (2012)
Journal Article

There is an increasing need for development of physiologically relevant in-vitro models for testing toxicity, however determining toxic effects of agents which undergo extensive hepatic metabolism can be particularly challenging. If a source of such... Read More about Development of a novel, physiologically relevant cytotoxicity model: Application to the study of chemotherapeutic damage to mesenchymal stromal cells.

Alkylating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells (2011)
Journal Article

The adverse effects of melphalan and cyclophosphamide on hematopoietic stem cells are well-known; however, the effects on the mesenchymal stem cells (MSCs) residing in the bone marrow are less well characterised. Examining the effects of chemotherape... Read More about Alkylating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells.

Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy (2010)
Journal Article
Hows, J., Wexler, S., Kemp, K. C., Morse, R., Wexler, S. A., Cox, C., …Donaldson, C. (2010). Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy. Annals of Hematology, 89(7), 701-713. https://doi.org/10.1007/s00277-009-0896-2

Hematopoietic recovery after high-dose chemotherapy (HDC) in the treatment of hematological diseases may be slow and/or incomplete. This is generally attributed to progressive hematopoietic stem cell failure, although defective hematopoiesis may be i... Read More about Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy.